Elequin Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Elequin Capital’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,510	Closed	-$15.3K	–	682
2022 Q4	$15.3K	Hold	1,510	–	–	﹤0.01%	435
2022 Q3	$15K	Buy	+1,510	New	+$14.9K	0.01%	202

Elequin Capital's BIOT Position: Q1 2023 in Review

Elequin Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 1,510 shares — an estimated $15.3K sold.

Elequin Capital first reported a position in BIOT in Q3 2022 and held it in 2 quarters. The position peaked at $15.3K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Elequin Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Elequin Capital sold 1,510 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $15.3K.
Elequin Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2022 and held it in 2 quarters.
Elequin Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $15.3K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Elequin Capital's 13F filing for Q1 2023, filed 11 May 2023.